Pharmocann Global Ltd reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was ILS 14.41 million compared to ILS 22.66 million a year ago. Net loss was ILS 9.73 million compared to ILS 25.26 million a year ago.

Basic loss per share from continuing operations was ILS 4.95 compared to ILS 28.02 a year ago. Diluted loss per share from continuing operations was ILS 4.95 compared to ILS 28.02 a year ago.